Intervention

Carboplatin AUC 6

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsNCT03081689 · 2017-04-15

COMPLETED

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)NCT02862457 · 2016-08-23

COMPLETED

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination ChemotherapyNCT00424840 · 2006-06-01

TERMINATED

Common conditions

Carcinoma, Non-Small-Cell Lung1 Lung Cancer1 Neoplasms1 Non Small Cell Lung Cancer1

Leading sponsors

Merck Sharp & Dohme LLC1 Spanish Lung Cancer Group1 University of Massachusetts, Worcester1

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

PHASE12

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.